Sunesis Pharmaceuticals (SNSS) : 1 brokerage houses believe that Sunesis Pharmaceuticals (SNSS) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Sunesis Pharmaceuticals (SNSS). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 3 Wall Street Analysts endorse the stock as a Buy with a rating of 2.33.
Sunesis Pharmaceuticals (NASDAQ:SNSS): The stock opened at $0.53 on Wednesday but the bulls could not build on the opening and the stock topped out at $0.55 for the day. The stock traded down to $0.50 during the day, due to lack of any buying support eventually closed down at $0.52 with a loss of -1.87% for the day. The stock had closed at $0.53 on the previous day. The total traded volume was 414,359 shares.
The company shares have dropped -82.85% from its 1 Year high price. On Jul 14, 2015, the shares registered one year high at $3.72 and the one year low was seen on May 16, 2016. The 50-Day Moving Average price is $0.54 and the 200 Day Moving Average price is recorded at $0.64.
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Companys program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin is an AQD, which is used for the treatment of cancer. MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Brutons tyrosine kinase (BTK). PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration.